1887

Chapter 120 : Chimerism Testing

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Chimerism Testing, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH120-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH120-2.gif

Abstract:

Chimerism testing is routinely used after allogeneic hematopoietic stem cell transplantation (HSCT) to monitor engraftment, detect relapse, identify patients with increased risk for graft-versus-host disease or graft loss, and monitor the effectiveness of therapeutic interventions. Chimerism testing can also be useful in other settings, such as detecting engraftment of donor lymphocytes after organ transplantation and determining sample identity (e.g., investigating suspected sample exchanges).

Citation: Baxter-Lowe L. 2016. Chimerism Testing, p 1161-1168. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch120
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

STR alleles differ in their lengths due to differences in the numbers of tandemly repeated sequence motifs. This figure shows a simple STR, which is referred to as a tetranucleotide repeat because there are 4 nucleotides in the motif. STRs used for chimerism testing are usually dinucleotide, trinucleotide, tetranucleotide, or pentanucleotide repeats.

Citation: Baxter-Lowe L. 2016. Chimerism Testing, p 1161-1168. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch120
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Identifying informative STR loci. Electropherograms of a multiplex PCR for four STR loci are shown for an HSCT recipient (top) and donor (bottom). For D21S11, the donor and recipient are homozygous for alleles of the same length (223 bp). For D18S51, the recipient is homozygous for an allele that is 285 bp. The donor shares this allele and has an additional allele that is 302 bp. Thus, D18S51 is a donor-informative locus. For D16S539, the donor and recipient share an allele that is 364 bp, and there are informative alleles for the donor (360 bp) and recipient (352 bp). For Penta D, there are two informative alleles for the recipient (422 and 441 bp) and the donor (394 and 417 bp).

Citation: Baxter-Lowe L. 2016. Chimerism Testing, p 1161-1168. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch120
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555818722.ch120
1. Tilanus MG. 2006. Short tandem repeat markers in diagnostics: what's in a repeat? Leukemia 20:13531355.[CrossRef].[PubMed]
2. Willasch A, Eing S, Weber G, Kuçi S, Schneider G, Soerensen J, Jarisch A, Rettinger E, Koehl U, Klingebiel T, Kreyenberg H, Bader P. 2010. Enrichment of cell subpopulations applying automated MACS technique: purity, recovery and applicability for PCR-based chimerism analysis. Bone Marrow Transplant 45:181189.[CrossRef].[PubMed]
3. Lion T, Watzinger F, Preuner S, Kreyenberg H, Tilanus M, de Weger R, van Loon J, de Vries L, Cavé H, Acquaviva C, Lawler M, Crampe M, Serra A, Saglio B, Colnaghi F, Biondi A, van Dongen JJ, van der Burg M, Gonzalez M, Alcoceba M, Barbany G, Hermanson M, Roosnek E, Steward C, Harvey J, Frommlet F, Bader P. 2012. The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. Leukemia 26:18211828.[CrossRef].[PubMed]
4. van der Burg M, Kreyenberg H, Willasch A, Barendregt BH, Preuner S, Watzinger F, Lion T, Roosnek E, Harvey J, Alcoceba M, Díaz MG, Bader P, van Dongen JJ EU-Supported EuroChimerism Consortium Project QLRT-2001-01485. 2011. Standardization of DNA isolation from low cell numbers for chimerism analysis by PCR of short tandem repeats. Leukemia 25:14671470.[CrossRef].[PubMed]
5. Khan F, Liacini A, Arora E, Wang S, Assad M, Doulla J, Faridi RM, Berka N. 2012. Assessment of fidelity and utility of the whole-genome amplification for the clinical tests offered in a histocompatibility and immunogenetics laboratory. Tissue Antigens 79:372379.[CrossRef].[PubMed]
6. Nagy M, Rascon J, Massenkeil G, Ebell W, Roewer L. 2006. Evaluation of whole-genome amplification of low-copy-number DNA in chimerism analysis after allogeneic stem cell transplantation using STR marker typing. Electrophoresis 27:30283037.[CrossRef].[PubMed]
7. Thiede C, Florek M, Bornhäuser M, Ritter M, Mohr B, Brendel C, Ehninger G, Neubauer A. 1999. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 23:10551060.[CrossRef].[PubMed]
8. Nollet F, Billiet J, Selleslag D, Criel A. 2001. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transplant 28:511518.[CrossRef].[PubMed]
9. Scharf SJ, Smith AG, Hansen JA, McFarland C, Erlich HA. 1995. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 85:19541963.[PubMed]
10. Thiede C, Bornhäuser M, Ehninger G. 2004. Evaluation of STR informativity for chimerism testing—comparative analysis of 27 STR systems in 203 matched related donor recipient pairs. Leukemia 18:248254.[CrossRef].[PubMed]
11. Schraml E, Lion T. 2003. Interference of dye-associated fluorescence signals with quantitative analysis of chimerism by capillary electrophoresis. Leukemia 17:221223.[CrossRef].[PubMed]
12. Thiede C, Bornhäuser M, Ehninger G. 2004. Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation. Acta Haematol 112:1623.[CrossRef].[PubMed]
13. Pereira S, Vayntrub T, Hiraki DD, Cherry AM, Arai S, Dvorak CC, Grumet FC. 2011. Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants. Hum Immunol 72:503509.[CrossRef].[PubMed]
14. Watzinger F, Lion T, Steward C Eurochimerism Consortium. 2006. The RSD code: proposal for a nomenclature of allelic configurations in STR-PCR-based chimerism testing after allogeneic stem cell transplantation. Leukemia 20:14481452.[CrossRef].[PubMed]
15. Lipshutz GS, Baxter-Lowe LA, Nguyen T, Jones KD, Ascher NL, Feng S. 2003. Death from donor-transmitted malignancy despite emergency liver retransplantation. Liver Transplant 9:11021107.[CrossRef]
16. Much M, Buza N, Hui P. 2014. Tissue identity testing of cancer by short tandem repeat polymorphism: pitfalls of interpretation in the presence of microsatellite instability. Hum Pathol 45:549555.[CrossRef].[PubMed]
17. Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, Weisdorf D. 2001. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 7:473485.[CrossRef].[PubMed]
18. Kroger N, Bacher U, Bader P, Bottcher S, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS. 2010. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I. Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 16:11871211.[CrossRef].[PubMed]
19. Kroger N, Bacher U, Bader P, Bottcher S, Borowitz MJ, Dreger P, Khouri I, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS. 2010. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part II. Chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant 16:13251346.[CrossRef].[PubMed]
20. Lion T, Daxberger H, Dubovsky J, Filipcik P, Fritsch G, Printz D, Peters C, Matthes-Martin S, Lawitschka A, Gadner H. 2001. Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia 15:307310.[PubMed].[CrossRef]
21. Breuer S, Preuner S, Fritsch G, Daxberger H, Koenig M, Poetschger U, Lawitschka A, Peters C, Mann G, Lion T, Matthes-Martin S. 2012. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia 26:509519.[CrossRef].[PubMed]
22. Matthes-Martin S, Lion T, Haas OA, Frommlet F, Daxberger H, König M, Printz D, Scharner D, Eichstill C, Peters C, Lawitschka A, Gadner H, Fritsch G. 2003. Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection. Leukemia 17:19341942.[CrossRef].[PubMed]
23. Lawler M, McCann SR, Marsh JC, Ljungman P, Hows J, Vandenberghe E, O'Riordan J, Locasciulli A, Socié G, Kelly A, Schrezenmeier H, Marin P, Tichelli A, Passweg JR, Dickenson A, Ryan J, Bacigalupo A Severe Aplastic Anaemia Working Party of the European Blood and Marrow Transplant Group. 2009. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br J Haematol 144:933945.[CrossRef].[PubMed]
24. Baron F, Maris MB, Storer BE, Sandmaier BM, Panse JP, Chauncey TR, Sorror M, Little MT, Maloney DG, Storb R, Heimfeld S. 2005. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 19:822828.[CrossRef].[PubMed]
25. Lion T. 2007. Detection of impending graft rejection and relapse by lineage-specific chimerism analysis. Methods Mol Med 134:197216.[PubMed].[CrossRef]
26. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, Kremens B, Dilloo D, Sykora KW, Schrappe M, Niemeyer C, Von Stackelberg A, Gruhn B, Henze G, Greil J, Niethammer D, Dietz K, Beck JF, Klingebiel T. 2004. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 22:16961705.[CrossRef].[PubMed]
27. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Kremens B, Dilloo D, Sykora KW, Niemeyer C, Reinhardt D, Vormoor J, Gruhn B, Lang P, Greil J, Handgretinger R, Niethammer D, Klingebiel T, Beck JF. 2004. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant 33:815821.[CrossRef].[PubMed]
28. Horn B, Soni S, Khan S, Petrovic A, Breslin N, Cowan M, Pelle-Day G, Cooperstein E, Baxter-Lowe LA. 2009. Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies. Bone Marrow Transplant 43:469476.[CrossRef].[PubMed]
29. Ozyurek E, Cowan MJ, Koerper MA, Baxter-Lowe LA, Dvorak CC, Horn BN. 2008. Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders. Bone Marrow Transplant 42:8391.[CrossRef].[PubMed]
30. Hanson V, Adams B, Lord J, Barker A, Poulton K, Lee H. 2013. Assessment of the purity of isolated cell populations for lineage-specific chimerism monitoring post haematopoietic stem cell transplantation. Tissue Antigens 82:269275.[CrossRef].[PubMed]
31. Ruiz ADS, Chauffaille MDLF, Alves ST, Oliveira JS. 2009. Prevalence of chimerism after non-myeloablative hematopoietic stem cell transplantation. Sao Paulo Med J 127:251258.[PubMed]
32. Buño I, Nava P, Simón A, González-Rivera M, Jiménez JL, Balsalobre P, Serrano D, Carrión R, Gómez-Pineda A, Díez-Martín JL. 2005. A comparison of fluorescent in situ hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell transplantation. Haematologica 90:13731379.[PubMed]
33. Cotteret S, Belloc F, Boiron JM, Bilhou-Nabera C, Dumain P, Boyer C, Lacombe F, Reiffers J, Bernard P. 1998. Fluorescent in situ hybridization on flow-sorted cells as a tool for evaluating minimal residual disease or chimerism after allogenic bone marrow transplantation. Cytometry 34:216222.[PubMed].[CrossRef]
34. Lee TH, Chafets DM, Reed W, Wen L, Yang Y, Chen J, Utter GH, Owings JT, Busch MP. 2006. Enhanced ascertainment of microchimerism with real-time quantitative polymerase chain reaction amplification of insertion-deletion polymorphisms. Transfusion 46:18701878.[CrossRef].[PubMed]
35. Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C, Lamy T, Le Prisé PY, Beauplet A, Bories D, Semana G, Quelvennec E. 2002. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 99:46184625.[PubMed].[CrossRef]
36. Gendzekhadze K, Gaidulis L, Senitzer D. 2013. Chimerism testing by quantitative PCR using Indel markers. Methods Mol Biol 1034:221237.[CrossRef].[PubMed]
37. Maas F, Schaap N, Kolen S, Zoetbrood A, Buño I, Dolstra H, de Witte T, Schattenberg A, van de Wiel-van Kemenade E. 2003. Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. Leukemia 17:621629.[CrossRef].[PubMed]
38. Hancock JP, Goulden NJ, Oakhill A, Steward CG. 2003. Quantitative analysis of chimerism after allogeneic bone marrow transplantation using immunomagnetic selection and fluorescent microsatellite. PCR Leukemia 17:247251.[CrossRef].[PubMed]
39. Kreyenberg H, Hölle W, Möhrle S, Niethammer D, Bader P. 2003. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experience. Leukemia 17:237240.[CrossRef].[PubMed]
40. Baxter-Lowe LA, Busch MP. 2006. Tracking microchimeric DNA in plasma to diagnose and manage organ transplant rejection Clin Chem 52:559561.[CrossRef].[PubMed]
41. Nelson JL. 2003. Microchimerism in human health and disease. Autoimmunity 36:59.[PubMed].[CrossRef]
42. Reed WF, Lee TL, Trachtenberg E, Vinson M, Busch MP. 2001. Detection of microchimerism by PCR is a function of amplification strategy. Transfusion 41:3944.[PubMed].[CrossRef]
43. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL, Tewari M. 2013. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 10:10031005.[CrossRef].[PubMed]
44. Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, Gaedcke J, Moerer O, Slotta JE, Walson P, Kollmar O, Oellerich M, Schütz E. 2013. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem 59:17321741.[CrossRef].[PubMed]
45. George D, Czech J, John B, Yu M, Jennings LJ. 2013. Detection and quantification of chimerism by droplet digital PCR. Chimerism 4:102108.[CrossRef].[PubMed]
46. Hochberg EP, Miklos DB, Neuberg D, Eichner DA, McLaughlin SF, Mattes-Ritz A, Alyea EP, Antin JH, Soiffer RJ, Ritz J. 2003. A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood 101:363369.[CrossRef].[PubMed]
47. Wu CJ, Hochberg EP, Rogers SA, Kutok JL, Biernacki M, Nascimento AF, Marks P, Bridges K, Ritz J. 2003. Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp Hematol 31:924933.[PubMed].[CrossRef]
48. Rieneck K, Bak M, Jønson L, Clausen FB, Krog GR, Tommerup N, Nielsen LK, Hedegaard M, Dziegiel MH. 2013. Next-generation sequencing: proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma. Transfusion 53(Suppl 2):28922898.[CrossRef].[PubMed]
49. Bentley G, Higuchi R, Hoglund B, Goodridge D, Sayer D, Trachtenberg EA, Erlich HA. 2009. High-resolution, high-throughput HLA genotyping by next-generation sequencing. Tissue Antigens 74:393403.[CrossRef].[PubMed]
50. Schumm M, Feuchtinger T, Pfeiffer M, Hoelle W, Bethge W, Ebinger M, Kuci S, Handgretinger R, Lang P. 2007. Flow cytometry with anti HLA-antibodies: a simple but highly sensitive method for monitoring chimerism and minimal residual disease after HLA-mismatched stem cell transplantation. Bone Marrow Transplant 39:767773.[CrossRef].[PubMed]
51. Metes D, Logar A, Rudert WA, Zeevi A, Woodward J, Demetris AJ, Abu-Elmagd K, Eghtesad B, Shapiro R, Fung JJ, Trucco M, Starzl TE, Murase N. 2003. Four-color flow cytometric analysis of peripheral blood donor cell chimerism. Hum Immunol 64:787795.[PubMed].[CrossRef]
52. Kawai T, Sachs DH. 2013. Tolerance induction: hematopoietic chimerism. Curr Opin Organ Transplant 18:402407.[CrossRef].[PubMed]
53. Domiati-Saad R, Klintmalm GB, Netto G, Agura ED, Chinnakotla S, Smith DM. 2005. Acute graft versus host disease after liver transplantation: patterns of lymphocyte chimerism. Am J Transplant 5:29682973.[CrossRef].[PubMed]
54. Nelson JL. 2012. The otherness of self: microchimerism in health and disease. Trends Immunol 33:421427.[CrossRef].[PubMed]
55. Lee TH, Paglieroni T, Ohto H, Holland PV, Busch MP. 1999. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood 93:31273139.[PubMed]
56. Utter GH, Owings JT, Lee TH, Paglieroni TG, Reed WF, Gosselin RC, Holland PV, Busch MP. 2004. Blood transfusion is associated with donor leukocyte microchimerism in trauma patients. J Trauma 57:702708.[PubMed].[CrossRef]

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error